Wir danken von ganzem Herzen allen Spendern!
Donating is NOT possible anymore!
100% will go to the University of Erlangen for the establishment of a study "BC007 in ME/CFS".
There are about 300,000 ME/CFS sufferers in Germany who are currently without help.
Conducting a study with the drug BC007 for ME/CFS sufferers.
A drug that has already led to success in long-covid patients
ME/CFS (Myalgische Enzephalomyelitis / Chronisches Fatigue Syndrom) is a serious multi-system disease with devastating effects on the lives of those affected. Symptoms range from complete exhaustion, inability to sit or stand, disorders of the blood circulation regulation, palpitations, strong head, muscle, tendon and nerve pain, dizziness, tinnitus, intermittent paralysis, seizures, burning sensation on the skin, visual and hearing disorders up to to irritation and sensitivity to light, severe concentration disorders and much more. Symptoms gradually worsen with exertion. Affected people can no longer participate in public life and become care cases. ME/CFS can reach a stage where people can no longer speak or eat.
Although classified as neuro-immunological by the WHO in 1969, this serious disease has remained without support, clinical research and treatment to this day. In Germany there are around 300,000 people affected, 40,000 of whom are children and young people. Worldwide there are an estimated 17 million!
Long-Covid, the disease that occurs in around 10% of those infected after infection with the SARS-CoV-2 virus, has resulted in thousands upon thousands developing the full picture of ME/CFS since the beginning of the pandemic.
In mid-September 2021, the German Federal Ministry of Education and Research (BMBF) launched a study to research the drug BC 007 under the direction of Dr. Dr. med. Bettina Hohberger at the University Hospital Erlangen, but ONLY for patients affected by Long-Covid. Unfortunately, this means that ME/CFS patients who have been seriously ill for years and decades for a cure cannot be included in the study despite the large overlap between the two clinical pictures.
We want to change that! Miss Dr. Hohberger would also like to help those affected and set up a study for ME/CFS.
EXPANSION OF STUDY - Through private donations and politics
(As of April 6th, 2022)
We will continue to collect donations until the end of May 2022, also with the funding amount of €800,000 decided by Bavarian state politics on April 6th, 2022. – The actual amount transferred to Erlangen is €720,000. – We thank you very much for that.
The money collected through the fundraiser "We demand research" will be transferred to a foundation account at the University Hospital Erlangen. Everything that goes beyond the originally specified minimum amount also serves to implement extensions of the study, which we aim to be as comprehensive as possible (e.g.: further doses of the drug BC007 in the event of recurrence of the autoantibodies, longer course of the study, extension of the follow-up observations, supplementation of examinations and follow-up examinations).
We have already achieved a great deal and look forward to your donations, which we urgently need.
Many many thanks!
The #fundraisingbc007MEcfs team
For more information see the FAQ.
Brückeverbindet e.V. advocates for people in need of care and helps in Berlin with volunteer everyday companions who provide those in need of care with household-related services and assistance.
Brückeverbindet e.V. c/o Alexander Graef Blankenburger Str. 9 13156 Berlin
Phone: 030/ 39742968
Email: info@bruecke-verbindet.de